Illumina Stock News

Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Illumina Announces Co-Development Partnership With SomaScan For Accelerating Proteomics Illumina, Inc. (NASDAQ: ILMN ) announced it has entered into a definitive co-development agreement with SomaLogic to bring the SomaScan Proteomics Assay onto Illumina''s current and future high throughput next-generation sequencing platforms. This partnership accelerates the rapidly growing high throughput sector of the proteomics market. With the scale and speed of Illumina NGS technology, researchers can more effectively and efficiently make biological connections from genetic sequence to cellular function and accelerate opportunities for clinical impact, Illumina said. Lilly Announces R&D Collaboration With Entos To Develop Neurological Drug Eli Lilly and Company (NYSE: LLY ) said it has acquired exclusive rights to Entos Pharmaceuticals'' Fusogenix nucleic acid delivery technology to research, develop and commercialize nucleic acid products targeting the central and peripheral nervous system.

Futures Steady After Fed-Inspired Rout As Tech, Bitcoin Slide Continues US equity futures were little changed after earlier swings as traders digested hawkish Fed minutes that sparked a global stock rout on Wednesday. As discussed yesterday, minutes from the Feds December meeting showed a growing preference for a faster path of rate hikes and a shrinking of the banks balance sheet (one which would lead to yet another market crash and even more stimulus). However, while rising rates is terrible news for tech and high duration names, it''s good news for the value sector, and investors bet while the Fed''s faster-than-expected policy tightening (which will lead to faster than expected easing) may crimp highly valued technology stocks it will offer opportunities in other equity sectors, and sure enough with Nasdaq futures bombing again, energy names like Exxon are at 2 year highs. Treasury yields extended a spike, with the 10Y rising to 1.75%, the dollar was unchanged and bitcoin''s plunge continued even though the selling in stocks has subsided.

In the current market session, Illumina Inc. (NASDAQ:ILMN) is trading at $370.29, after a 0.65% increase. However, over the past month, the

Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Illumina Announces Co-Development Partnership With

By Kimberly Chin SomaLogic Inc.''s shares rose 13% after hours to $11.69 after the company said it has partnered with Illumina Inc., a genomic sequencing and

SomaLogic (SLGC) and Illumina (ILMN) are collaborating to develop sequencing-based proteomic solutions.The financial terms of the transaction were not disclosed.The multi-year

Co-developed and co-branded products to combine market-leading proteomic and genomic analysis platforms Co-developed and co-branded products to combine market-leading proteomic and genomic analysis platforms

DUBLIN , Jan. 5, 2022 /PRNewswire/ -- The "Cancer Microbiome Sequencing Market - A Global and Regional Analysis: Focus on Offering, Application, Technology, End User, and Region - Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com''s offering. In 2020, the global cancer microbiome sequencing market was valued at $155.5 million , and it is expected to reach $1,216.2 million by 2031, growing at a CAGR of 20.01% during the forecast period 2021-2031. The market is driven by certain factors, including increasing emphasis on the microbiome''s potential in cancer, global increase in cancer prevalence, and decreasing cost of sequencing. Currently, the cancer microbiome sequencing industry is witnessing an upsurge due to the increasing emphasis on the microbiome''s potential in the field of cancer, global increase in cancer prevalence, and decreasing cost of sequencing. Furthermore, biotechnology companies are focusing on developing cancer microbiome sequencing solutions for applications, including translational research and diagnostics, further supporting researchers and clinicians to unravel insights pertaining to microbiome''s influence on cancer manifestation and progression.

Illumina's (ILMN) recent collaboration will explore the real-world uptake and actionability of comprehensive genomic profiling in patients with advanced cancer.

The collaboration will explore the uptake and actionability of comprehensive genomic profiling in patients with advanced cancers The collaboration will explore the uptake and actionability of comprehensive genomic profiling in patients with advanced cancers

Someone with a lot of money to spend has taken a bullish stance on Illumina (NASDAQ:ILMN). And retail traders should know. We noticed this today when the

The "India Oncology NGS Market Size, Share & Trends Analysis Report by End-use (Clinical Research, Hospitals & Clinics), Technology, Application, Product & Service, Workflow, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com''s offering. The Indian oncology NGS market is expected to reach USD 70.60 million by 2028, registering a CAGR of 19.6% over the forecast period, according to the report. The development of companion diagnostic assays for personalized medicine, growing adoption of sequencing platforms for cancer diagnosis, and increasing investment for the development of genomic databases are the key driving factors for market growth. The increasing need for user-friendly sequencing workflows along with cost-effective solutions contribute to the rising adoption rate of this technology in India. The availability of the genome database for the Indian population eases the process of developing companion diagnostics & personalized medicine and offers access to stratified samples for the research.

Detecting toxic stocks and dumping them at the right time is crucial to avoid big losses. ILMN, TCMD, CTOS and GCI are a few toxic stocks that don't deserve a place in your portfolio.

ROBO: Beware Of Risks Surrounding The Seemingly Promising Theme